Cocrystal Capital Surpluse from 2010 to 2025

COCP Stock  USD 1.48  0.08  5.13%   
Cocrystal Pharma Capital Surpluse yearly trend continues to be relatively stable with very little volatility. Capital Surpluse is likely to drop to about 215.9 M. During the period from 2010 to 2025, Cocrystal Pharma Capital Surpluse destribution of quarterly values had range of 323.2 M from its regression line and mean deviation of  105,073,432. View All Fundamentals
 
Capital Surpluse  
First Reported
2011-06-30
Previous Quarter
336.1 M
Current Value
342 M
Quarterly Volatility
104.8 M
 
Yuan Drop
 
Covid
Check Cocrystal Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cocrystal Pharma's main balance sheet or income statement drivers, such as Interest Expense of 1.7 K, Selling General Administrative of 4.1 M or Selling And Marketing Expenses of 8.9 M, as well as many indicators such as Price To Sales Ratio of 383, Dividend Yield of 0.0 or PTB Ratio of 0.69. Cocrystal financial statements analysis is a perfect complement when working with Cocrystal Pharma Valuation or Volatility modules.
  
Check out the analysis of Cocrystal Pharma Correlation against competitors.
To learn how to invest in Cocrystal Stock, please use our How to Invest in Cocrystal Pharma guide.

Latest Cocrystal Pharma's Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of Cocrystal Pharma over the last few years. It is Cocrystal Pharma's Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cocrystal Pharma's overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

Cocrystal Capital Surpluse Regression Statistics

Arithmetic Mean193,950,379
Geometric Mean128,543,070
Coefficient Of Variation62.49
Mean Deviation105,073,432
Median243,419,000
Standard Deviation121,202,894
Sample Variance14690.1T
Range323.2M
R-Value0.85
Mean Square Error4433.5T
R-Squared0.72
Significance0.000034
Slope21,576,308
Total Sum of Squares220352.1T

Cocrystal Capital Surpluse History

2025215.9 M
2024341.9 M
2020297.3 M
2019260.9 M
2018253.9 M
2017243.4 M
2016239 M

About Cocrystal Pharma Financial Statements

Cocrystal Pharma shareholders use historical fundamental indicators, such as Capital Surpluse, to determine how well the company is positioned to perform in the future. Although Cocrystal Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in Cocrystal Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Cocrystal Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Capital Surpluse341.9 M215.9 M

Additional Tools for Cocrystal Stock Analysis

When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.